Clostridium butyricum is a potentially beneficial gut bacterium that may promote gut health and suppress H. pylori, but there may be some safety concerns. Learn more here.
Clostridium butyricum is a butyric acid-producing, Gram-positive bacteria found in soil and the intestines of healthy animals and humans .
Butyrate (butyric acid) is a short-chain fatty acid (SCFA) that serves as energy for colonic epithelial cells, plays a key role in maintaining gut immunological homeostasis, and exerts anti-inflammatory effect .
Furthermore, butyrate is not restricted to the intestinal tract but can be disseminated systemically and is detected in the brain. Butyrate in the brain can exert neuroprotective effects on neurodegenerative disorders and improve behavioral deficits via the inhibition of histone deacetylases (HDACs) .
Clinical research about C. butyricum is still pretty limited, but you can check out the benefits of butyrate here.
Tablets containing C. butyricum were approved from the Japanese Ministry of Health and Welfare for human clinical use since 1970  and are widely used in Asia.
C. butyricum probiotic supplements have not been approved by the FDA for medical use. Supplements generally lack solid clinical research. Regulations set manufacturing standards for them but don’t guarantee that they’re safe or effective. Speak with your doctor before supplementing.
SelfDecode has an AI-powered app that allows you to see how C. butyricum may benefit your personal genetic predispositions. These are all based on clinical trials. The red sad faces denote genetic weaknesses that C. butyricum may counteract.
Concomitant administration of C. butyricum with antibiotics normalizes the intestinal microbiota, prevents the decrease of Bifidobacteria, effectively prevented antibiotic-associated diarrhea in 110 children .
In 80 ulcerative colitis (UC) patients with food allergy, specific immunotherapy (SIT) and C. butyricum significantly improved UC clinical symptoms, reduced the use of UC-control medicines, and suppressed the Th2 response .
Probiotic therapy with C. butyricum achieved favorable results with minimal side effects in 17 pouchitis in patients with UC who had undergone ileal pouch-anal anastomosis (IPAA) .
C. butyricum increases Lactobacilli and Eubacterium, increases n-butyrate, propionate, and acetate concentrations, and alleviates colitis in rats .
Treatment with C. butyricum is at least as efficient as treatment with mesalamine in rats with colitis .
C. butyricum increased survival in E. coli infected mice .
The following purported benefits are only supported by limited, low-quality clinical studies. There is insufficient evidence to support the use of C. butyricum probiotics for any of the below-listed uses. Remember to speak with a doctor before taking probiotics, and never use them in place of something your doctor recommends or prescribes.
The combined use of C. butyricum reduced the changes in the intestinal flora and decreased the incidence of gastrointestinal side effects in patients going through H. pylori eradication therapy .
C. butyricum prevented the side effects of H. pylori eradication therapy, including antibiotic-associated diarrhea, in 19 patients .
C. butyricum inhibited the growth of H. pylori and eradicated persistent H. pylori infection in mice .
C. butyricum alleviated gastric mucosal damage and ameliorates symptoms in mice with gastric ulcers, through its anti-oxidative and anti-inflammatory activities. This bacterium alleviates oxidative stress by increasing the activity of superoxide dismutase and catalases and decreasing malondialdehyde levels [16, 17].
C. butyricum improved asthma and serum specific IgE in the patients treated with specific immunotherapy (SIT), increases IL-10, and converts antigen-specific B cells to regulatory B cells .
C. butyricum markedly enhanced the efficacy of SIT on allergic rhinitis in 158 patients with allergies .
Administration of C. butyricum enforced the inhibitory effect of SIT on allergic inflammation in the mouse intestine .
No clinical evidence supports the use of C. butyricum for any of the conditions listed in this section. Below is a summary of the existing animal and cell-based research, which should guide further investigational efforts. However, the studies listed below should not be interpreted as supportive of any health benefit.
C. butyricum restores butyrate in the brain, increases BDNF levels, reduces neuronal cell death, and significantly attenuates the cognitive dysfunction and histopathological changes in mice with vascular dementia .
C. butyricum exerts neuroprotective effects against ischemia/reperfusion injury in mice through antioxidant and anti-apoptotic (cell-death-preventing) mechanisms, and by increasing butyrate contents in the brain .
C. butyricum attenuates cognitive impairment, cell damage and prevents cell death in diabetic mice with cerebral ischemia/reperfusion injury .
C. butyricum reduced fat accumulation in liver and blood, lowered insulin levels and improved glucose tolerance and insulin sensitivity in obese mice. Furthermore, C. butyricum administration ameliorated GI and fat tissue inflammation .
C. butyricum can reduce lipogenesis (fat production) through its metabolites such as butyrate .
Furthermore, in mice, co-treatment with C. butyricum and Bacillus subtilis inhibits the development of colorectal cancer .
C. butyricum was also shown to kill bladder cancer cells. However, cell studies very rarely have any relevance for cancer therapies in animals or humans .
Researchers have investigated the potential mechanisms of C. butyricum’s benefits in cell and animal studies. They have found that this probiotic:
- Increased BCL-2 [3, 21] and p-AKT [3, 22] in the brain.
- Decreased BAX [3, 21] and caspase-3 [22, 21] in the brain.
- Increased IL-10 [7, 18, 2] and IL-22 .
- Decreased TNF-α [2, 17, 11, 2], IL1-β [17, 2], IL-6 , IL-23 , MCP-1 , and LBT4 .
- Increased 6-keto-PGF-1α , PPAR α/γ, LXR-α , and ANGPTL4 .
- Decreased MDA [17, 21].
- Increased SOD and CAT [21, 17].
- Decreased CGPR , DGAT2 , and TLR4 .
Note that not all C. butyricum strains are safe for consumption. Whereas non-toxigenic strains are currently used as probiotics in Asia, other strains have been implicated in pathological conditions, such as botulism in infants or necrotizing enterocolitis in preterm neonates .
C. butyricum MIYAIRI 588 (or CBM 588) are safe for use as a probiotic in humans .
To avoid adverse effects, talk to your doctor before using C. butyricum probiotics.
Buy C. butyricum
These products contain C. butyricum: